Hypertension after renal transplantation

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hypertension affects nearly 90% of renal graft recipients under current immunosuppression protocols.
• Key contributors include impaired renal function, calcineurin inhibitors, renin secretion, transplant artery stenosis, polycythemia, and donor genetic predisposition.
• Even mild blood pressure elevation significantly impacts recipient and graft survival by exacerbating vascular injury.

Purpose of the Study:

• To review the causes and management strategies for hypertension in renal allograft recipients.
• To highlight the significance of systolic blood pressure and circadian blood pressure profiles.
• To provide updated treatment recommendations, including the role of ACE inhibitors.

Main Methods:

• Literature review of causes and management of hypertension in renal transplant recipients.
• Analysis of factors contributing to elevated blood pressure post-transplantation.
• Evaluation of current and recommended antihypertensive therapies.

Main Results:

• Impaired renal function, immunosuppressants (calcineurin inhibitors), renin-angiotensin system activation, and vascular issues are primary drivers of hypertension.
• Elevated systolic blood pressure and abnormal circadian patterns are particularly detrimental to graft and recipient outcomes.
• ACE inhibitors are now indicated, alongside diuretics and calcium channel blockers, which remain central to treatment.

Conclusions:

• Hypertension is a critical complication in renal transplantation with multifactorial causes.
• Effective blood pressure management is essential for improving long-term graft and recipient survival.
• A combination of antihypertensive agents, including ACE inhibitors, diuretics, and calcium channel blockers, is recommended.